APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

Report ID 174006740322 December 2025198 pages

Choose your research edition.

Industry ResearchLeber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Research Report 2026129 pages · $2,950 USDIndustry Growth & TrendsGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) include Alkeus Pharmaceuticals, Biovista, Editas Medicine, GenSight Biologics, Ixchel Pharma, Khondrion, Mitotech, ProQR Therapeutics and Spark Therapeutics, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market size, projected growth trends, production technologies, key applications, and end-use industries.

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Company

Alkeus Pharmaceuticals

Biovista

Editas Medicine

GenSight Biologics

Ixchel Pharma

Khondrion

Mitotech

ProQR Therapeutics

Spark Therapeutics

Stealth BioTherapeutics

Usher Syndrome

Amgen

Sanofi

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Type

Dominant Optic Atrophy

Recessive Optic Atrophy

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Application

Hospitals

Medical Research Institute

Eye Clinics

Other

Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends Table 2. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Drivers Table 3. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Opportunities and Challenges Table 4. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Restraints Table 5. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Manufacturers (k pcs) & (2021-2026) Table 8. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Manufacturers Table 9. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Sales Price (US$/pcs) of Manufacturers (2021-2026) Table 10. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Manufacturers, Product Type & Application Table 13. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Dominant Optic Atrophy Table 17. Major Manufacturers of Recessive Optic Atrophy Table 18. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type 2021 VS 2025 VS 2032 (k pcs) Table 19. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2021-2026) & (k pcs) Table 20. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2027-2032) & (k pcs) Table 21. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Type (2021-2026) Table 22. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Type (2027-2032) Table 23. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type 2021 VS 2025 VS 2032 (k pcs) Table 24. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2021-2026) & (k pcs) Table 25. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2027-2032) & (k pcs) Table 26. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Type (2021-2026) Table 27. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Type (2027-2032) Table 28. Major Manufacturers of Hospitals Table 29. Major Manufacturers of Medical Research Institute Table 30. Major Manufacturers of Eye Clinics Table 31. Major Manufacturers of Other Table 32. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application 2021 VS 2025 VS 2032 (k pcs) Table 33. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2021-2026) & (k pcs) Table 34. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2027-2032) & (k pcs) Table 35. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Application (2021-2026) Table 36. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Application (2027-2032) Table 37. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application 2021 VS 2025 VS 2032 (k pcs) Table 38. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2021-2026) & (k pcs) Table 39. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2027-2032) & (k pcs) Table 40. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Application (2021-2026) Table 41. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Application (2027-2032) Table 42. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021 VS 2025 VS 2032 (k pcs) Table 43. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2021-2026) & (k pcs) Table 44. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Region (2021-2026) Table 45. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Forecasted by Region (2027-2032) & (k pcs) Table 46. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Forecasted Market Share by Region (2027-2032) Table 47. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 48. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026) & (k pcs) Table 49. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032) & (k pcs) Table 50. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 51. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026) & (k pcs) Table 52. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032) & (k pcs) Table 53. Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 54. Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026) & (k pcs) Table 55. Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032) & (k pcs) Table 56. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (k pcs) Table 57. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2026) & (k pcs) Table 58. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2027-2032) & (k pcs) Table 59. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 60. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region (2021-2026) & (US$ Million) Table 61. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region (2027-2032) & (US$ Million) Table 62. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Region (2021-2026) Table 63. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Region (2027-2032) Table 64. Alkeus Pharmaceuticals Company Information Table 65. Alkeus Pharmaceuticals Business Overview Table 66. Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 68. Alkeus Pharmaceuticals Recent Development Table 69. Biovista Company Information Table 70. Biovista Business Overview Table 71. Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 73. Biovista Recent Development Table 74. Editas Medicine Company Information Table 75. Editas Medicine Business Overview Table 76. Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 78. Editas Medicine Recent Development Table 79. GenSight Biologics Company Information Table 80. GenSight Biologics Business Overview Table 81. GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 83. GenSight Biologics Recent Development Table 84. Ixchel Pharma Company Information Table 85. Ixchel Pharma Business Overview Table 86. Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 88. Ixchel Pharma Recent Development Table 89. Khondrion Company Information Table 90. Khondrion Business Overview Table 91. Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 92. Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 93. Khondrion Recent Development Table 94. Mitotech Company Information Table 95. Mitotech Business Overview Table 96. Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 97. Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 98. Mitotech Recent Development Table 99. ProQR Therapeutics Company Information Table 100. ProQR Therapeutics Business Overview Table 101. ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 102. ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 103. ProQR Therapeutics Recent Development Table 104. Spark Therapeutics Company Information Table 105. Spark Therapeutics Business Overview Table 106. Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 107. Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 108. Spark Therapeutics Recent Development Table 109. Stealth BioTherapeutics Company Information Table 110. Stealth BioTherapeutics Business Overview Table 111. Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 112. Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 113. Stealth BioTherapeutics Recent Development Table 114. Usher Syndrome Company Information Table 115. Usher Syndrome Business Overview Table 116. Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 117. Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 118. Usher Syndrome Recent Development Table 119. Amgen Company Information Table 120. Amgen Business Overview Table 121. Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 122. Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 123. Amgen Recent Development Table 124. Sanofi Company Information Table 125. Sanofi Business Overview Table 126. Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (k pcs), Price (US$/pcs), Revenue (US$ Million) and Gross Margin (2021-2026) Table 127. Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio Table 128. Sanofi Recent Development Table 129. Key Raw Materials Table 130. Raw Materials Key Suppliers Table 131. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors List Table 132. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers List Table 133. Research Programs/Design for This Report Table 134. Authors List of This Report Table 135. Secondary Sources Table 136. Primary Sources List of Figures Figure 1. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Image Figure 2. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size (2021-2032) & (US$ Million) Figure 4. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales (2021-2032) & (k pcs) Figure 5. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Price (US$/pcs) & (2021-2032) Figure 6. Global Top 5 and 10 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Dominant Optic Atrophy Image Figure 9. Recessive Optic Atrophy Image Figure 10. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 11. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share 2021 VS 2025 VS 2032 Figure 12. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Type (2021-2032) Figure 13. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2021 VS 2025 VS 2032) & (k pcs) Figure 14. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share 2021 VS 2025 VS 2032 Figure 15. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Type (2021-2032) Figure 16. Hospitals Image Figure 17. Medical Research Institute Image Figure 18. Eye Clinics Image Figure 19. Other Image Figure 20. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 21. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share 2021 VS 2025 VS 2032 Figure 22. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Application (2021-2032) Figure 23. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2021 VS 2025 VS 2032) & (k pcs) Figure 24. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share 2021 VS 2025 VS 2032 Figure 25. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Application (2021-2032) Figure 26. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 27. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2021-2032) Figure 28. U.S. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 29. Canada Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 30. Mexico Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 31. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 32. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2021-2032) Figure 33. Germany Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 34. France Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 35. U.K. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 36. Italy Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 37. Netherlands Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 38. Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 39. Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2021-2032) Figure 40. China Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 41. Japan Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 42. South Korea Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 43. Southeast Asia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 44. India Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 45. Australia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 46. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 47. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Country (2021-2032) Figure 48. Brazil Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 49. South Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 50. Saudi Arabia Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 51. Turkey Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 52. Argentina Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 53. UAE Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 54. Egypt Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 55. Chile Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales and Growth Rate (2021-2032) & (k pcs) Figure 56. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 57. Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 58. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032) & (US$ Million) Figure 59. North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 60. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032) & (US$ Million) Figure 61. Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032) & (US$ Million) Figure 63. Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032) & (US$ Million) Figure 65. South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Value Chain Figure 67. Manufacturing Cost Structure Figure 68. Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Production Mode & Process Figure 69. Direct Comparison with Distribution Share Figure 70. Distributors Profiles Figure 71. Years Considered Figure 72. Research Process Figure 73. Key Executives Interviewed

Scope & coverage.

Types
  • Dominant Optic Atrophy
  • Recessive Optic Atrophy
Applications
  • Hospitals
  • Medical Research Institute
  • Eye Clinics
  • Other
Companies covered
  • Alkeus Pharmaceuticals
  • Biovista
  • Editas Medicine
  • GenSight Biologics
  • Ixchel Pharma
  • Khondrion
  • Mitotech
  • ProQR Therapeutics
  • Spark Therapeutics
  • Stealth BioTherapeutics
  • Usher Syndrome
  • Amgen
  • Sanofi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market Dynamics
  1. 2.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Trends
  2. 2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Drivers
  3. 2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Opportunities and Challenges
  4. 2.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Restraints
3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Manufacturers
  1. 3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Manufacturers, Product Type & Application
  7. 3.7 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Tier 1, Tier 2, and Tier 3
4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Type
  1. 4.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Type Introduction
  2. 4.1.1 Dominant Optic Atrophy
  3. 4.1.2 Recessive Optic Atrophy
  4. 4.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type
  5. 4.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Type (2021-2032)
  7. 4.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Type (2021-2032)
  8. 4.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type
  9. 4.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Type (2021-2032)
  11. 4.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Type (2021-2032)
5 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Market by Application
  1. 5.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Application Introduction
  2. 5.1.1 Hospitals
  3. 5.1.2 Medical Research Institute
  4. 5.1.3 Eye Clinics
  5. 5.1.4 Other
  6. 5.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application
  7. 5.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Application (2021-2032)
  9. 5.2.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Market Share by Application (2021-2032)
  10. 5.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application
  11. 5.3.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Application (2021-2032)
  13. 5.3.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Application (2021-2032)
6 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region
  1. 6.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2021-2032)
  3. 6.2.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Region (2021-2026)
  4. 6.2.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region
  1. 7.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region
  2. 7.1.1 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region (2021-2026)
  4. 7.1.3 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue by Region (2027-2032)
  5. 7.1.4 Global Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032)
  8. 7.2.2 North America Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032)
  11. 7.3.2 Europe Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Alkeus Pharmaceuticals
  2. 8.1.1 Alkeus Pharmaceuticals Company Information
  3. 8.1.2 Alkeus Pharmaceuticals Business Overview
  4. 8.1.3 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Alkeus Pharmaceuticals Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  6. 8.1.5 Alkeus Pharmaceuticals Recent Developments
  7. 8.2 Biovista
  8. 8.2.1 Biovista Company Information
  9. 8.2.2 Biovista Business Overview
  10. 8.2.3 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Biovista Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  12. 8.2.5 Biovista Recent Developments
  13. 8.3 Editas Medicine
  14. 8.3.1 Editas Medicine Company Information
  15. 8.3.2 Editas Medicine Business Overview
  16. 8.3.3 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Editas Medicine Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  18. 8.3.5 Editas Medicine Recent Developments
  19. 8.4 GenSight Biologics
  20. 8.4.1 GenSight Biologics Company Information
  21. 8.4.2 GenSight Biologics Business Overview
  22. 8.4.3 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 GenSight Biologics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  24. 8.4.5 GenSight Biologics Recent Developments
  25. 8.5 Ixchel Pharma
  26. 8.5.1 Ixchel Pharma Company Information
  27. 8.5.2 Ixchel Pharma Business Overview
  28. 8.5.3 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Ixchel Pharma Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  30. 8.5.5 Ixchel Pharma Recent Developments
  31. 8.6 Khondrion
  32. 8.6.1 Khondrion Company Information
  33. 8.6.2 Khondrion Business Overview
  34. 8.6.3 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Khondrion Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  36. 8.6.5 Khondrion Recent Developments
  37. 8.7 Mitotech
  38. 8.7.1 Mitotech Company Information
  39. 8.7.2 Mitotech Business Overview
  40. 8.7.3 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mitotech Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  42. 8.7.5 Mitotech Recent Developments
  43. 8.8 ProQR Therapeutics
  44. 8.8.1 ProQR Therapeutics Company Information
  45. 8.8.2 ProQR Therapeutics Business Overview
  46. 8.8.3 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProQR Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  48. 8.8.5 ProQR Therapeutics Recent Developments
  49. 8.9 Spark Therapeutics
  50. 8.9.1 Spark Therapeutics Company Information
  51. 8.9.2 Spark Therapeutics Business Overview
  52. 8.9.3 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Spark Therapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  54. 8.9.5 Spark Therapeutics Recent Developments
  55. 8.10 Stealth BioTherapeutics
  56. 8.10.1 Stealth BioTherapeutics Company Information
  57. 8.10.2 Stealth BioTherapeutics Business Overview
  58. 8.10.3 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Stealth BioTherapeutics Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  60. 8.10.5 Stealth BioTherapeutics Recent Developments
  61. 8.11 Usher Syndrome
  62. 8.11.1 Usher Syndrome Company Information
  63. 8.11.2 Usher Syndrome Business Overview
  64. 8.11.3 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Usher Syndrome Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  66. 8.11.5 Usher Syndrome Recent Developments
  67. 8.12 Amgen
  68. 8.12.1 Amgen Company Information
  69. 8.12.2 Amgen Business Overview
  70. 8.12.3 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Amgen Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  72. 8.12.5 Amgen Recent Developments
  73. 8.13 Sanofi
  74. 8.13.1 Sanofi Company Information
  75. 8.13.2 Sanofi Business Overview
  76. 8.13.3 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Sanofi Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Product Portfolio
  78. 8.13.5 Sanofi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Value Chain Analysis
  2. 9.1.1 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Production Mode & Process
  6. 9.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Distributors
  9. 9.2.3 Leber’s Hereditary Optic Neuropathy (LHON) (Leber Optic Atrophy) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst